Exact Sciences shares are trading higher after the company said its Cologuard test demonstrated 94% sensitivity for colorectal cancer at 91% specificity.
Portfolio Pulse from Benzinga Newsdesk
Exact Sciences' Cologuard test demonstrated 94% sensitivity for colorectal cancer at 91% specificity, leading to a rise in the company's shares.
June 21, 2023 | 8:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exact Sciences shares are trading higher after the company's Cologuard test showed 94% sensitivity for colorectal cancer at 91% specificity.
The positive results of the Cologuard test indicate a strong product offering by Exact Sciences, which could lead to increased demand and revenue for the company. This news is likely to boost investor confidence in the stock, resulting in a short-term positive impact on the share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100